Accurate personalized survival prediction for amyotrophic lateral sclerosis patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Accurate personalized survival prediction for amyotrophic lateral sclerosis patients ; volume:13 ; number:1 ; day:24 ; month:11 ; year:2023 ; pages:1-7 ; date:12.2023
Scientific reports ; 13, Heft 1 (24.11.2023), 1-7, 12.2023
- Creator
-
Kuan, Li-Hao
Parnianpour, Pedram
Kushol, Rafsanjany
Kumar, Neeraj
Anand, Tanushka
Kalra, Sanjay
Greiner, Russell
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-023-47935-7
- URN
-
urn:nbn:de:101:1-2024020714443833405700
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kuan, Li-Hao
- Parnianpour, Pedram
- Kushol, Rafsanjany
- Kumar, Neeraj
- Anand, Tanushka
- Kalra, Sanjay
- Greiner, Russell
- SpringerLink (Online service)
Other Objects (12)
Equipoise Is a Slippery Eel
Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial
Discrimination and diabetes: Insight from the second Diabetes Attitudes Wishes and Needs (DAWN2) Study
Mishti copes with diabetes: A pragmatic approach to coping skills training
Therapy in type 2 diabetes: A logical empiricism - based approach
Higher, sweeter, heavier: Not necessarily healthier
Erratum to: Auxiliendo, Primum Non Nocere: A Preliminary View of the DEVOTE Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Type 2 Diabetes
Mishti copes with diabetes: Dancing
Diabetes: Exploring social and psychological domain
The alcohol and tobacco burden of India
Auxiliendo, Primum Non Nocere: A Preliminary View of the DEVOTE Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Type 2 Diabetes
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
Equipoise Is a Slippery Eel
Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial
Discrimination and diabetes: Insight from the second Diabetes Attitudes Wishes and Needs (DAWN2) Study
Mishti copes with diabetes: A pragmatic approach to coping skills training
Therapy in type 2 diabetes: A logical empiricism - based approach
Higher, sweeter, heavier: Not necessarily healthier
Erratum to: Auxiliendo, Primum Non Nocere: A Preliminary View of the DEVOTE Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Type 2 Diabetes
Mishti copes with diabetes: Dancing
Diabetes: Exploring social and psychological domain
The alcohol and tobacco burden of India
Auxiliendo, Primum Non Nocere: A Preliminary View of the DEVOTE Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Type 2 Diabetes
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
Equipoise Is a Slippery Eel
Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial
Discrimination and diabetes: Insight from the second Diabetes Attitudes Wishes and Needs (DAWN2) Study
Mishti copes with diabetes: A pragmatic approach to coping skills training
Therapy in type 2 diabetes: A logical empiricism - based approach
Higher, sweeter, heavier: Not necessarily healthier
Erratum to: Auxiliendo, Primum Non Nocere: A Preliminary View of the DEVOTE Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Type 2 Diabetes
Mishti copes with diabetes: Dancing
Diabetes: Exploring social and psychological domain
The alcohol and tobacco burden of India
Auxiliendo, Primum Non Nocere: A Preliminary View of the DEVOTE Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Type 2 Diabetes